PharmaTher Receives FDA Approval Goal Date for Ketamine

An update from PharmaTher Holdings Ltd ( (TSE:PHRM) ) is now available.

PharmaTher Holdings Ltd. announced that it has received an Amendment Acknowledgement Letter from the U.S. FDA for its New Drug Application for Ketamine, with an approval goal date set for June 4, 2025. This development positions PharmaTher to potentially become a leading supplier of Ketamine in the U.S., addressing the ongoing shortage and filling the demand gap. The company has addressed minor deficiencies noted by the FDA and aims to remove Ketamine from the FDA’s drug shortage list, which would restrict compound pharmacies from supplying it, thereby strengthening PharmaTher’s market position.

More about PharmaTher Holdings Ltd

PharmaTher Holdings Ltd. is a specialty pharmaceutical company focused on the development and commercialization of KETARX™ (Ketamine) to address unmet medical needs in surgery, pain, mental health, neurological, and medical countermeasures indications.

YTD Price Performance: -10.67%

Average Trading Volume: 161,771

Technical Sentiment Consensus Rating: Buy

Current Market Cap: $11.66M

Learn more about PHRM stock on TipRanks’ Stock Analysis page.